Mylan – Global Pharmaceutical Company
Mylan
Mylan is an American pharmaceutical company founded in 1961 in West Virginia by Milan Puskar and Don Panoz. For many years it was headquartered in Pennsylvania. In November 2020 Mylan combined with Upjohn, Pfizer's off-patent medicines division, to form Viatris, headquartered in Canonsburg, Pennsylvania. Products registered earlier continue to be sold under the Mylan name.
Mylan made generic and branded medicines across many therapy areas, including antiretrovirals for HIV. It grew through major acquisitions: in 2007 it took control of the Indian API maker Matrix Laboratories — at the time the largest takeover in India's pharmaceutical industry — and bought Merck KGaA's generics business, followed by the Swedish company Meda in 2016.
In India, Mylan products are marketed by the local company Mylan Pharmaceuticals. In December 2017 it launched HepBest (tenofovir alafenamide) for chronic hepatitis B in adults — the first new drug for the disease approved in India in eight years. A month earlier, in November 2017, it launched Abevmy, a bevacizumab biosimilar co-developed with India's Biocon. In 2022 Viatris transferred its biosimilars business to Biocon Biologics.
Unifarm carries Mylan's Abevmy 400 (bevacizumab) and HepBest (tenofovir alafenamide).